Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 Nov 2018

Mathias M C, Collins P W, Palmer B P, Chalmers E, Alamelu J, Richards M, Will A, Hay C R M

Abstract excerpt

INTRODUCTION: Factor VIII inhibitor development is currently the most serious complication of the treatment of haemophilia A. Differences in manufacturing and the molecular structure of brands of recombinant factor VIII have led to speculation that concentrates may differ in immunogenicity. This has led to a regulatory focus on the immunogenicity of factor VIII concentrates both before and after licensure. AIM:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Factor VIII

Share to Hemophilia A

Share to Infant

Share to Time Factors

Share to United Kingdom

Source

Identifiers

PMID: 30004617
DOI: 10.1111/hae.13551

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.PMID 30004617Read ↗

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.Semantic proximity Read ↗

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.Semantic proximity Read ↗

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII.Semantic proximity Read ↗

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.Semantic proximity Read ↗

Key insights to understand the immunogenicity of FVIII products.Semantic proximity Read ↗

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia ASemantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Treatment related factors and inhibitor development in children with severe haemophilia A.Semantic proximity Read ↗

Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.Semantic proximity Read ↗

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.Semantic proximity Read ↗

Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesSemantic proximity Read ↗

SIPPET: methodology, analysis and generalizabilitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.